Suchen
Grifols SA
GRFSZur Watchlist hinzufügen
7.870USD
-0.330-4.02%
Handelsschluss 07-31 16:00（ET）Kurse um 15 Minuten verzögert
2.03BMarktkapitalisierung
10.14KGV TTM
mehr Informationen über Grifols SA Unternehmen
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Grifols SA Informationen
BörsenkürzelGRFS
Name des UnternehmensGrifols SA
IPO-datumMay 17, 2006
CEOAbia (Jose Ignacio)
Anzahl der mitarbeiter23833
WertpapierartDepository Receipt
GeschäftsjahresendeMay 17
AddresseParque Empresarial Can Sant Joan
StadtSANT CUGAT DEL VALLES
BörseNASDAQ OMX - NASDAQ BASIC
LandSpain
Postleitzahl08174
Telefon34935710000
Websitehttps://www.grifols.com/
BörsenkürzelGRFS
IPO-datumMay 17, 2006
CEOAbia (Jose Ignacio)
Führungskräfte von Grifols SA
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Nuria Martin Barnes
Ms. Nuria Martin Barnes
Non-Member Secretary of the Board of Directors
Non-Member Secretary of the Board of Directors
--
--
Mr. Ignacio Ramal Subira
Mr. Ignacio Ramal Subira
Chief Internal Audit & Enterprise Risk Management
Chief Internal Audit & Enterprise Risk Management
--
--
Mr. David Ian Bell
Mr. David Ian Bell
Chief Corporate Affairs and Legal Officer
Chief Corporate Affairs and Legal Officer
--
--
Mr. Inigo Sanchez-Asiain Mardones
Mr. Inigo Sanchez-Asiain Mardones
Independent Director
Independent Director
--
--
Mr. Victor Grifols Deu
Mr. Victor Grifols Deu
Proprietary Director
Proprietary Director
--
--
Ms. Enriqueta Felip Font
Ms. Enriqueta Felip Font
Independent Director
Independent Director
--
--
Ms. Maria Teresa Rione Llano
Ms. Maria Teresa Rione Llano
Chief Communications Officer
Chief Communications Officer
--
--
Mr. Daniel Fleta Coit
Mr. Daniel Fleta Coit
Chief Industrial Services Officer
Chief Industrial Services Officer
--
--
Mr. Albert Grifols Coma-Cros
Mr. Albert Grifols Coma-Cros
Proprietary Director
Proprietary Director
--
--
Mr. Antonio Martinez Martinez, Ph.D.
Mr. Antonio Martinez Martinez, Ph.D.
President - Diagnostic
President - Diagnostic
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Nuria Martin Barnes
Ms. Nuria Martin Barnes
Non-Member Secretary of the Board of Directors
Non-Member Secretary of the Board of Directors
--
--
Mr. Ignacio Ramal Subira
Mr. Ignacio Ramal Subira
Chief Internal Audit & Enterprise Risk Management
Chief Internal Audit & Enterprise Risk Management
--
--
Mr. David Ian Bell
Mr. David Ian Bell
Chief Corporate Affairs and Legal Officer
Chief Corporate Affairs and Legal Officer
--
--
Mr. Inigo Sanchez-Asiain Mardones
Mr. Inigo Sanchez-Asiain Mardones
Independent Director
Independent Director
--
--
Mr. Victor Grifols Deu
Mr. Victor Grifols Deu
Proprietary Director
Proprietary Director
--
--
Ms. Enriqueta Felip Font
Ms. Enriqueta Felip Font
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Grifols SA?
Die fünf größten Anteilseigner von Grifols SA sind: Ms. Nuria Martin Barnes
Wie viele Institutionen halten Anteile an Grifols SA (GRFS)?
Mit Stand vom 2026Q1 halten 346 Institutionen Anteile an Grifols SA, mit einem Gesamtmarktwert von etwa 148.94M, was 57.68% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -8688154.00 gestiegen.